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In this study we used magnetic resonance imaging (MRI)
biomarkers to monitor the acute temporal changes in tumor
vascular physiology with the aim of identifying the vascular
signatures that predict response to combined anti-angiogenic
and radiation treatments. Forty-three athymic rats implanted
with orthotopic U-251 glioma cells were studied for approx-
imately 21 days after implantation. Two MRI studies were
performed on each animal, pre- and post-treatment, to
measure tumor vascular parameters. Two animal groups
received treatment comprised of Cilengitide, an anti-angio-
genic agent and radiation. The first group received a
subcurative regimen of Cilengitide 1 h before irradiation,
while the second group received a curative regimen of
Cilengitide 8 h before irradiation. Cilengitide was given as a
single dose (4 mg/kg; intraperitoneal) after the pretreatment
MRI study and before receiving a 20 Gy radiation dose. After
irradiation, the post-treatment MRI study was performed at
selected time points: 2, 4, 8 and 12 h (n¼5 per time point).
Significant changes in vascular parameters were observed at
early time points after combined treatments in both
treatment groups (1 and 8 h). The temporal changes in
vascular parameters in the first group (treated 1 h before
exposure) resembled a previously reported pattern associated
with radiation exposure alone. Conversely, in the second
group (treated 8 h before exposure), all vascular parameters
showed an initial response at 2–4 h postirradiation, followed
by an apparent lack of response at later time points. The
signature time point to define the ‘‘synergy’’ of Cilengitide
and radiation was 4 h postirradiation. For example, 4 h after
combined treatments using a 1 h separation (which followed
the subcurative regimen), tumor blood flow was significantly
decreased, nearly 50% below baseline (P¼ 0.007), whereas 4
h after combined treatments using an 8 h separation (which
followed the curative regimen), tumor blood flow was only
10% less than baseline. Comparison between the first and
second groups further revealed that most other vascular
parameters were maximally different 4 h after combined
treatments. In conclusion, the data are consistent with the
assertion that the delivery of radiation at the vascular
normalization time window of Cilengitide improves radiation
treatment outcome. The different vascular responses after the
different delivery times of combined treatments in light of the
known tumor responses under similar conditions would
indicate that timing has a crucial influence on treatment
outcome and long-term survival. Tracking acute changes in
tumor physiology after monotherapy or combined treatments
appears to aid in identifying the beneficial timing for
administration, and perhaps has predictive value. Therefore,
judicial timing of treatments may result in optimal treatment
response.  2017 by Radiation Research Society
INTRODUCTION
Glioblastoma (GBM) remains one of the most lethal
cancers, with a 15-month average overall survival (OS),
even with optimal treatment (1). The combination of
therapies are more effective than a monotherapy in treating
GBM and improving patient OS and quality of life (2, 3). In
preclinical studies, the optimum short-term order and timing
of combined treatments can significantly influence OS (4–
6). Since these potential ‘‘synergies’’ are short-term with
respect to tumor response, and many of the agents affect
tumor vasculature, it might be expected that the short-term
changes in tumor physiology which occur in response to
combined treatments could be used as biomarkers of
response. Indeed, studies in preclinical models (7, 8)
showed that tumor physiology changes profoundly in the
hours after either anti-angiogenic treatment or irradiation. In
current clinical practice, short-term anatomical changes
don’t occur and short-term physiological responses are not
1 Address for correspondence: Henry Ford Hospital, Department of
Radiation Oncology, 2799 West Grand Blvd. Detroit, MI 48202-
2689; email: sbrown1@hfhs.org.
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usually assessed. Instead, a delayed assessment (weeks or
months later) based on tumor volume, e.g., the response
evaluation criteria in solid tumors (RECIST) (9, 10), or
more recently, revised assessment in neuro-oncology
(RANO) (11, 12) criteria, is used to evaluate responses.
Cilengitide is an anti-angiogenic agent which, when
combined with radiation in preclinical studies, has been
shown to increase OS compared to radiation treatment
alone (4). It has multimodal anti-glioma effects such as
cytotoxic, anti-angiogenic, anti-invasive and synergistic
effects (13). Mikkelsen et al. (4) reported that a single
injection of Cilengitide given 4–12 h before irradiation had
a therapeutic benefit when combined with radiation in a U-
251 cerebral glioma model. However, when Cilengitide
was administered outside that time window, it showed
little additional effect on OS. Nagaraja et al. observed
short-term effects of Cilengitide on the tumor vasculature
of U-251 cerebral glioma in athymic rats, demonstrating
that it exerted a short-term effect on transvascular transfer
parameters of the tumor vasculature, causing vascular
normalization at approximately 8 h after treatment (7). It
has been suggested that normalization of the vasculature
increased radiosensitivity and enhanced treatment efficacy
(14).
The importance of optimizing the timing and sequence
of combined therapies such as radiotherapy with anti-
angiogenic drugs has become increasingly recognized (15–
18), as has the importance of acute tumor responses to
therapies (4, 5, 7, 8, 19). In this study, we investigated the
timing between Cilengitide and radiation exposure to
determine the vascular signature corresponding to in-
creased tumor response to combined treatments. Dynamic
contrast-enhanced magnetic resonance imaging (DCE-
MRI) with model selection (20–22) along with Patlak et
al. (23, 24) and Logan et al. (25, 26) graphical methods
were used to measure tumor vascular parameters in a U-
251 rat model of embedded cerebral tumor. Based on the
duration of time between Cilengitide treatment and
radiation exposure, the effects on tumor vascular physiol-
ogy were evaluated in two groups, one associated with a
sub-curative response (drug given 1 h before irradiation),
and one associated with a curative response (drug given 8
h before irradiation). Acute changes in tumor vascular
parameters were monitored in the hours after the combined
treatments to detect responses.
MATERIALS AND METHODS
These studies were approved by the Henry Ford Hospital
Institutional Animal Care and Use Committee (IACUC). Forty-three
athymic rats were intracerebrally inoculated with U-251 tumor cells.
Approximately three weeks after implantation, two MRI studies were
performed 24 h apart for each animal, with MRI vascular parameters
measured in the two sessions. Animals were exposed to radiation as
the second part of the combined treatments at 2, 4, 8 or 12 h before the
second MRI. Immediately after the second MRI session, the brain of
the anesthetized animal was removed for histology.
The U-251 Orthotopic Brain Tumor Model
Athymic nude rats (n ¼ 43) (;8 weeks old; Charles River
Laboratories, Wilmington, MA) were implanted intracerebrally with
U-251 MG tumor cells. Animals were anesthetized with isoflurane
(4% for induction, 0.75–1.5% for maintenance, balance N2O:O2 ¼
2:1). The surgical zone was swabbed with Betadinet solution, the eyes
coated with Lacri-Lubet and the head immobilized in a small animal
stereotactic device (Kopft Instruments, Tujunga, CA). After draping,
a 1 cm incision was made 2 mm to the right of the midline and the
skull was exposed. A burr hole was drilled 3.5 mm to the right of
bregma, taking care not to penetrate the dura mater. A 10 ll Hamilton
syringe with a 26g needle (model no. 701, Hamilton Co., Reno, NV)
containing U-251 MG tumor cells freshly harvested from log phase
growth (53 105 in 10 ll of PBS) was lowered to a depth of 3.0 mm
and then raised back to a depth of 2.5 mm to create a pocket. Cells
were injected at a rate of 0.5 ll/10 s until the entire volume was
injected. The syringe was then slowly withdrawn, the burr hole sealed
with sterile bone wax and the skin sutured. Tumors in animals
implanted following this technique grew to 3–5 mm diameter in
approximately 3 weeks after implantation.
Between day 18 and 21 after implantation, two MRI studies were
performed 24 h apart for each animal. Animals were anesthetized with
isoflurane (4% for induction, 0.75–1.5% for maintenance, balance
N2O:O2¼ 2:1) and allowed to spontaneously respire. A tail vein was
cannulated for the administration of the contrast agent. Body
temperature was maintained constant (378C) with a warm air supply
monitored via an intrarectal type T thermocouple.
Treatment Protocol
Animals were divided into two groups, all animals received
Cilengitide and radiation treatments, the two groups were distin-
guished by the interval between administration of Cilengitide and time
of exposure to radiation.
Animals were exposed to radiation, at 1 (n¼ 21) and 8 h (n¼ 22),
after Cilengitide treatment. Each group was further divided into four
subgroups (n ¼ 5 or 6 per subgroup) according to the time point of
irradiation (2, 4, 8 and 12 h) preceding the second MRI. Thus, the
entire timeline of the studies falls within the 24 h time interval
between the two MRI studies. Figure 1 shows the timing of combined
treatments and MRIs for each group.
Cilengitide Administration
A single 4 mg/kg dose (i.p.) of Cilengitide was administered after
the pretreatment MRI study at 1 and 8 h preirradiation. Normal saline
was the diluent and the injected volume was 0.2 ml. Cilengitide was
purchased commercially from Selleck Chemicals (Houston, TX).
Radiation Treatment
The protocol for radiation treatment is described in detail in Brown
et al. (8). Briefly, radiation was delivered using a clinical linear
accelerator operating at 6 MV photons (Varian Trilogy, Palo Alto,
CA). The location of the tumor was determined from the pretreatment
MRI study, and referenced to the burr hole used to implant the tumor.
After anesthesia (80 mg/kg ketamine and 8 mg/kg xylazine), rats were
placed in a stereotactic device with the rat head in the same orientation
as when tumor cells were implanted. A total dose of 20 Gy was
delivered at an approximate dose rate of 8 Gy/min using 8 3 8 cm
primary collimation, a 6 mm diameter cone as a secondary collimator,
a source-to-surface distance of 75 cm, a 14 mm bolus above the skull
for electron equilibrium at the tumor depth and a linear accelerator
output rate set at 800 monitor units per min. The tumor dimensions
were covered by the 100% isodose line. The treatment beam projected
in a single anterior-posterior direction from the top of the skull through
the tumor on the right hemisphere exiting under the jaw.
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MRI Studies
All studies were performed using a Varian 7-Tesla MRI magnet
(Santa Clara, CA) 20 cm bore system with a DirectDrive spectrometer
and console. Gradient maximum strengths and rise times were 250 mT/
m and 120 ls. All MRI image sets were acquired with a 323 32 mm2
field of view. The transmit coil was a Bruker-supplied volume resonator
and the receive coil was a Bruker 2 cm surface coil for rat brain imaging
(Billerica, MA). Arterial spin labeling (ASL), DCE-MRI, Look-Locker
(LL), T1-weighted and diffusion weighted imaging (DWI) acquisitions
were used to describe the state of the vasculature after treatment.
Spin-echo arterial spin-labeled data were acquired to estimate
cerebral blood flow in a single central slice, as previously described
elsewhere (27). Sets of MRI parameters were obtained with alternating
gradients and frequency offsets in combinations of four, as follows:
matrix ¼ 128 3 64, one 1.0 mm slice, NA ¼ 2, TE/TR ¼ 24/1500.
Arterial labeling ¼ 1 s. Total time ¼ 13 min.
The DCE-MRI sequence was a dual-echo gradient-echo (2GE)
sequence, the ‘‘mgems’’ sequence in the Agilent VnmrJ library. The
2GE sequence acquired a set of three slices on 2 mm centers (1.8 mm
slice, 0.2 mm gap). The slice set was centered on the tumor and 150
image sets at 4.0 s intervals were acquired with the following
parameters: flip angle (FA)¼258, matrix¼128364, NE¼2, NA¼1,
TE1/TE2/TR¼2.0/4.0/60 ms. Total run time was 10 min. At image 15
of the 2GE sequence, a bolus injection of the contrast agent
(Magnevistt; Bayer HealthCare LLC, Wayne, NJ), 0.25 mmol/kg at
undiluted concentration, no flush, was performed by hand push,
followed by a slight draw-back. The purpose of the draw-back was to
equilibrate intravascular pressure and to allow confirmation that blood
was in the line and the injection was delivered intravascularly. Prior to
the DCE-MRI sequence, and immediately after, two LL sequences
were run so that a voxel-by-voxel estimate of longitudinal relaxation
time (T1) in the tissue could be made pre- and post-contrast agent
administration. LL sequence parameters were as follows: FA ¼ 158,
matrix 128 3 64, five 2.0 mm slices, no gap. NE ¼ 24 inversion-
recovery echoes on 50 ms intervals, TE/TR ¼ 4.0 ms/2,000 ms.
Prior to the pre-contrast LL sequence, and after the post-contrast LL
sequence, two high-resolution T1-weighted spin-echo images were
acquired before and after administration of the contrast agent with the
following parameters: FA¼458, 1808, matrix 2563192, 27 slices, 0.4
mm thickness, 0.1 mm gap, NE¼ 1, NA¼ 4, TE/TR¼ 16 ms/800 ms.
After the post-contrast LL sequence, a pulsed-gradient spin-echo DWI
sequence was run in three directions (x, y, z) to generate a parametric
map of apparent diffusion coefficient (ADC). DWI sequence
parameters were as follows: matrix 128 3 64, 13 slices, 0.8 mm
thickness, 0.2 mm gap, TR¼ 1,500 ms, TE¼ 40 ms, NE¼ 1, b-values
¼ 0, 600, 1,217 s/mm2, gradient amplitude ¼ 107 mT/m, gradient
duration ¼ 10 ms.
Tumor Vascular Parameters
The MRI vascular parameters were estimated using the following:
1. ASL for estimating tumor blood flow (TBF) (27, 28); 2. Patlak et
al., extended Patlak and Blasberg (23, 24) [identical to extended Tofts
et al. (31)] and Logan et al. analyses (25, 29, 30) of DCE-MRI data,
using a model-selection paradigm (20–22) to estimate the plasma
volume fraction (vp), forward volumetric transfer constant (K
trans),
interstitial volume fraction (ve) and extracellular volume fraction (VD);
and 3. DWI to estimate ADC. As previously noted elsewhere (30), the
extracellular volume fraction, VD, can be estimated using Logan plots;
herein, VD will be used as a biomarker of treatment response. VD has
been shown to correlate with tumor cellular density (r – –0.75, P ,
0.001), and to strongly correlate with the extended Tofts model (31)
estimate of vp þ ve (r ¼ 0.91, P , 0.001). However, it will become
clear that VD is a more stable estimate of extracellular volume than is
the sum vp þ ve.
Model selection generates maps of brain regions and labels them
with the number of parameters used to describe the data. This results
in regions that map: 1. Only plasma volume, vp (essentially normal
vasculature with no leakage, where the filling of the vasculature with
contrast agent in the plasma occurs), named as the model 1 region; 2.
vp and K
trans (tissue regions with leakage, but with only blood-to-brain
influx,), named as the model 2 region; or 3. vp, K
trans and ve (highly
leaky vessels with measurable reflux of contrast agent from the
interstitial space to the microvasculature), named as the model 3
region. Quantitative maps of MRI vascular parameters were generated
for pre- and post-treatment imaging sessions. The MRI slice with the
largest tumor cross-section was selected and the model 3 region of
interest (ROI) was used to define the extent of the tumor.
The advantage of using a model selection paradigm is that the
border between tumor and surrounding normal tissue can be well
defined by the changing permeability of the tissue, with the tumor
tissue typically permeable to a contrast agent, and the normal tissue
typically impermeable across the time of the 9 min study. In all
animals, post-contrast T1-weighted images and hematoxylin and eosin
(H&E)-stained sections were used to confirm the tumor ROI that was
defined by model selection. Figure 2 shows that the tumor boundary
on both H&E-stained and post-contrast T1-weighted images agreed
with the tumor boundary defined by the model 3 region.
Histology
After the second MRI study, the animals were continued on
isoflurane anesthesia and transcardially perfused with normal saline
followed by the fixative, 4% paraformaldehyde. After the brains were
carefully removed from the skull, they were stored overnight in the
fixative. Coronal slices (2 mm thick) through the tumor were obtained
using a rat-brain matrix (Activational Systems Inc., Warren, MI). The
brain tissue was processed using a Tissue-Tekt VIP processor and
embedded in paraffin. Sections (7 lm thick) were cut from the paraffin
block corresponding to the MRI slice and placed on Superfrost Plus
(Fisher Scientific, Pittsburgh, PA) slides. It contained the largest tumor
area and was H&E stained for evaluation of tumor ROIs. Images were
collected using a Nikont Eclipse E800 microscope equipped with
ACT1C software. A comparative ROI was chosen within the
contralateral hemisphere, usually within the caudate putamen. Both
FIG. 1. Experiment timeline. Cilengitide was administrated 1 h (panel A) or 8 h (panel B) prior to irradiation.
In both groups, post-treatment MRIs were performed at 2, 4, 8 or 12 h postirradiation. Of note, the time between
the two MRIs was consistently 24 h.
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13 low magnification of the entire coronal section and 103 high
magnification images were collected. Images were imported into
ImageJ version 1.43u (NIH, Bethesda, MD) and converted to 8 bits for
analysis.
Statistical Analysis
All MRI vascular parameters were measured in the model 3 ROI
and are reported as mean6 standard error of the mean (SEM) for both
pre- and post-treatment MRI sessions. Vascular measurements at the
time points after treatment were compared with pretreatment values
for the same rats.
To make the effect of an intervention easily understood, pre- and
post-treatment differences were computed as percentage changes. To
avoid bias, the percentage change was calculated as f(post – pre)/[23
(mean of post þ pre)]g% for each parameter, allowing a maximum
change of 6100%, but preserving the assumption that the two
samples (pre and post) were drawn from the same population.
Dividing the difference by the mean generates an unbiased estimator
of change because the sources of error in the numerator and
denominator are balanced. In contrast, the percentage change
calculated as [(post – pre)/(pre)]% is a biased estimator and strongly
influenced by the baseline value, since it has two sources of error in
numerator and one in denominator (32). In addition, Shapiro-Wilk
tests were performed to test normality in the percentage change data
computed by both methods for the 1 and 8 h groups. The null
hypothesis was that if the P value was .0.1, then the sample is more
likely to be normally distributed.
A paired t test was applied for all vascular parameters to determine
significances in the percentage change for each time point in the 1 and
8 h groups: at 2, 4, 8 and 12 h. Additionally, percentage differences
between the 1 and 8 h groups at 4 h postirradiation were tested using
an unpaired Student’s t test. Differences in P , 0.05 were considered
statistically significant. To illustrate the treatment responses in the 1
and 8 h groups, the mean percentage change at each time point was
plotted against time for all vascular parameters. Error bars on the
graphs represent the standard error of the mean percentage change for
each time point.
RESULTS
The temporal variation of tumor physiology in the two
groups (Cilengitide administered either 1 or 8 h before
irradiation) was studied by MRI at 2, 4, 8 and 12 h
postirradiation. An example of the parametric maps of
model selection, DCE-MRI vascular parameters Ktrans and
ve, TBF and ADC are shown in Fig. 3. Figure 3A and B
show representative pre- and post-treatment parametric
maps for animals selected from the 1 and 8 h treatment
groups, MRI studies performed at 4 h postirradiation.
The mean of the ASL-estimated tumor blood flow in the
ROIs of the pretreatment population of 43 animal studies
was 113.2 6 5.8 [ml/100 ml-min]. The DCE-MRI vascular
parameters in tumor prior to treatment were: Ktrans¼ (4.74 6
0.25) 3 10–2 [min–1]; ve ¼ 15.51 6 0.60%; VD ¼ 16.88 6
0.63%. The pretreatment ADC value was (2.52 6 0.07)3
10–3 [mm2/s]. Pretreatment values for all parameters across
animals were normally distributed.
As noted, to avoid bias the percentage change in
parametric estimates was calculated as f(post – pre)/[2 3
(mean of post þ pre)]g% instead of [(post – pre)/(pre)]%
(32). When the two methods were applied to our data and
compared, the latter method produced significantly non-
normally distributed data sets in two vascular parameters,
and it produced more skewed data in most vascular
parameters, as shown in Table 1.
Figure 4 shows the percentage change as a function of
time for the vascular parameters, TBF, Ktrans, ve, VD and
ADC, in the model 3 region, i.e., the tumor region of
interest, for 1 and 8 h treatment groups. Significant changes
in vascular parameters were observed at early hours in the 1
and 8 h treatment groups after the combination of
Cilengitide and radiation exposure.
In the 1 h group (Fig. 4A), TBF showed a significant
decrease of about 40 6 5% below the pretreatment levels at
2 h postirradiation (P¼ 0.001), and continued to decline to
50 6 10% at 4 h postirradiation (P¼ 0.007). Subsequently,
TBF increased markedly to pretreatment values at 8 and 12
h postirradiation, to the extent that the average TBF values
were not significantly different from pretreatment levels (P
. 0.10). Conversely, Ktrans increased above the pretreatment
values, reaching its maximum value of around 156 3% at 4
and 8 h, and then sharply declined to 10 6 4% below the
pretreatment level at 12 h postirradiation. Ktrans values
significantly increased above pretreatment values at 4 (P ¼
0.034) and 8 h (P ¼ 0.003) postirradiation. The temporal
profile of ve resembled that of K
trans; except that ve values
were much closer to the pretreatment levels and then
FIG. 2. Panel A: High-resolution post-contrast agent T1-weighted image. Panel B: H&E staining of a centrally
located tissue slice approximately corresponding to the central slice of the MRI study. Panel C: Model selection
map. Yellow indicates model 3 acceptance (regions associated with highly leaky vasculature along with
backflux), dark red indicates model 2 acceptance (bordered model 3 regions, showing leakage at reduced rates)
and red indicates model 1 acceptance (normal nonleaky brain tissue). Note the anatomical agreement in the
position and distribution of the tumor mass and boundary between the model 3 region, T1 MRI and H&E images.
The rat brain is approximately 1.5 cm across (transverse direction).
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reduced to 8 6 3% below pretreatment value at 12 h
postirradiation. There was no significant change throughout
the study in ve values before and after treatment. VD started
below pretreatment levels at 2 and 4 h, followed by an
increase to the pretreatment value at 8 h postirradiation, and
then a significant decline to 10 6 3% below pretreatment
level at 12 h postirradiation (P¼ 0.033). It appears that VD
and TBF changed together, up to 12 h postirradiation.
A marked difference in the pattern of vascular responses
between the two groups was apparent starting at 4 h
postirradiation. In the 8 h group (Fig. 4B), TBF at 2 h
postirradiation significantly decreased by about 33 6 10%
TABLE 1
Normality Test and Skewness for the Two Methods of Percentage Change in 1 and 8 h Groups for all MRI Vascular
Parameters
Shapiro-Wilk normality test (P value) Skewness
[(post – pre)/23(mean of post þ pre)]% [(post – pre)/(pre)]% [(post – pre)/23(mean of post þ pre)]% [(post – pre)/(pre)]%
1 h group
TBF 0.451 0.118 0.091 0.716
Ktrans 0.130 0.324 0.650 0.273
ve 0.849 0.446 0.103 0.540
VD 0.998 0.900 0.001 0.485
ADC 0.568 0.209 0.585 0.863
8 h group
TBF 0.762 0.083* 0.185 1.116**
Ktrans 0.210 0.070* 0.157 0.545
ve 0.964 0.591 0.045 0.589
VD 0.469 0.729 0.338 0.011
ADC 0.406 0.526 0.358 0.220
* Not normally distributed (P , 0.10).
** Significantly skewed.
FIG. 3. Representative sets of pre- and post-treatment parametric maps from the 1 (panel A) and 8 h (panel B)
groups at 4 h postirradiation. Maps from left to right: ADC, TBF, Ktrans, ve and model selection; pretreatment is
shown in the top row and post-treatment in the bottom row. The left scale bar is shared between ADC and TBF
maps for both sets, but has different scaling as indicated in the range for each. The right color scale bar is given
in common to Ktrans, ve and model selection maps, but also with different scaling for each parameter. For the
model selection map, yellow is model 3 acceptance, dark red is model 2 acceptance and red is model 1
acceptance. Note the improvement in TBF in the post-treatment map for the 8 h group and the lack of change
between pre- and post-treatment in Ktrans maps, which indicate vascular normalization and evidence of treatment
effect at this time point.
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from pretreatment levels (P ¼ 0.043), followed by an
increase to near pretreatment values at 4 h postirradiation (P
¼ 0.031). Afterward, TBF values remained near pretreat-
ment values. In contrast, Ktrans was elevated to 18 6 5%
over pretreatment values at 2 h postirradiation (P¼ 0.047),
and then declined to near pretreatment levels at 4 h
postirradiation and beyond. Similarly, ve and VD values
started slightly below pretreatment levels at 2 h postirradi-
ation and then significantly decreased at 4 h postirradiation
to 10 6 2% (P ¼ 0.008) and 23 6 3% (P ¼ 0.001) below
pretreatment values. Afterward, ve and VD returned to 5 6
2% (P ¼ 0.030) and 10 6 3% (P ¼ 0.036) below
pretreatment levels at 12 h postirradiation.
ADC was estimated in the 1 h and 8 h groups and showed
no change throughout the study (Fig. 4A and 4B). The
associated error bars were large and the trends were
unremarkable over the experiment period.
DISCUSSION
In clinical oncology, the timing of chemotherapy,
including antiangiogenic agents that affect tumor vascula-
ture, is seldom considered in relationship to the time of
radiotherapy. However, as the results of this investigation
indicate, timing can be critical to the resulting tumor
physiology, and consequently to tumor response. Identify-
ing the characteristic changes in tumor physiology after
combined treatments that optimize tumor response may lead
to synergies in treatment efficacy, and to significant
improvements in the control of solid tumors.
Published preclinical studies have shown that the
sequence and timing of anti-angiogenic drug and radiation
administration affects therapeutic outcome and OS (15–18).
Timing-dependent outcomes appear to be related to acute
changes in the tumor vascular physiology in the hours after
a monotreatment or combined treatments (4, 5, 7, 8, 19).
Furthermore, by tracking short-term changes in tumor
vascular physiology, a beneficial timing of the combined
therapies can be identified, leading to better treatment
outcome and OS.
In previously published work, DCE-MRI parameters have
been shown to be reliable early biomarkers of tumor
response to treatment (33–35); they can characterize tissue
vasculature and are sensitive to vascular changes related to
tumor angiogenesis. Here, an ASL estimate of TBF and
DCE-MRI estimates of Ktrans, ve and VD were used to
evaluate the temporal characteristics of the acute therapeutic
tumor response. Since each one of these parameters gives
insight into a separate physiological factor, examination of
the spectrum of MRI tumor biomarkers and changes in their
relationship to one another can illuminate the physiology of
a therapeutic response.
In this study, we chose two intervals between Cilengitide
treatment and irradiation, and attempted to identify acute
temporal changes in tumor vascular parameters in a U-251
cerebral glioma rat model. Our choice of the intervals
between Cilengitide treatment and irradiation was based on
a knowledge of the temporal profile of acute changes in the
tumor vascular parameters after Cilengitide treatment alone
reported by Nagaraja et al. (7), and of irradiation alone
reported by Brown et al. (8). Nagaraja and colleagues
tracked the short-term changes in the tumor vascular
parameters (Ktrans and ve) at 2, 4, 8, 12 and 24 h after
Cilengitide administration in an orthotopic U-251 glioma
model. They found that vascular parameters pivoted around
the 8 h time point, with 2 and 4 h groups showing increases,
12 and 24 h groups showing decreases and values at 8 h
being close to the pretreatment baseline values, indicating
that Cilengitide caused vascular normalization at 8 h after
treatment. This vascular normalization coincided with a
previously published study (4) in which increased treatment
efficacy and OS were reported when Cilengitide was given
within 4–12 h prior to irradiation. In support of this finding,
it was reported in a mouse model with a human GBM (36)
that the outcome of radiation treatment was superior when
administered during the time window of normalization. We
concluded that pharmacological ‘‘normalization’’ of vascu-
lature (14) had the potential to increase sensitivity to
radiation.
FIG. 4. Percentage change versus time in the MRI vascular parameters after combined Cilengitide and
radiation treatments in the tumor region of interest. Cilengitide was administered 1 (panel A) or 8 h (panel B)
before irradiation. The pattern of response in the 1 h group resembles that of irradiation alone [see fig. 2 in ref.
(7)], while the pattern of response in the 8 h group shows a preservation of the vascular parameters starting at 4 h
postirradiation and indicates a synergistic effect. *P , 0.05.
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Acute changes in tumor vascular parameters hours after
exposure to a single 20 Gy radiation dose in an orthotopic
U-251 brain tumor model were investigated by Brown et al.
(8). The parameters, TBF, Ktrans and ve were measured at 2,
4, 8, 12 and 24 h after irradiation and the temporal changes
were recorded; significant changes in all vascular parame-
ters were observed in the hours after the 20 Gy irradiation.
Since no synergy would be expected in the 1 h group, the
temporal profile of tumor vascular parameters would be
expected to be similar to that of irradiation alone. In
addition, a therapeutic benefit would be expected in the 8 h
group, and therefore, the temporal pattern of response
should be expected to reveal a signature of ‘‘synergy’’ in
Cilengitide and irradiation.
In the 1 h group (Fig. 4A), the pattern of the temporal
changes of tumor vascular parameters followed the same
trend as seen previously with irradiation alone, an initial
decrease in blood flow followed by a normalization of blood
flow at 8 h (8), whereas in the 8 h group (Fig. 4B), the
temporal changes in tumor vascular parameters showed a
much different pattern than in the 1 h group, and appear to
serve as a marker of the response to combined Cilengitide
and irradiation.
It is to be expected that, after exposure to a large dose of
radiation, a transient increase in the vascular permeability
will occur, associated with damage to tumor vasculature
(37). In the 8 h group, Ktrans was significantly elevated 2 h
postirradiation, but, unlike irradiation alone or in the 1 h
group, this was then followed by a sharp decline below the
pretreatment level at 4 h postirradiation, after which point it
remained essentially unchanged. A steep decrease in Ktrans
appears to be evidence of combined drug and radiation
treatment effect on tumor vasculature (35), probably
associated with normalization of the vasculature (38, 39).
The decrease in Ktrans was coincident with a significant
increase in TBF from 33–10% below pretreatment levels.
This observation was in agreement with another published
study (40), in which it was reported that vascular
normalization led to increased tumor perfusion and lower
tumor interstitial pressure. Vascular normalization and an
increase in tumor perfusion were associated with the
increase in OS (41). We suggest that irradiation 8 h after
the administration of Cilengitide decreases tumor vascular
permeability, leading to normalization of the vasculature
and improved tumor perfusion. The ‘‘lack’’ of response
(i.e., resetting and continuation) at 4 h postirradiation
indicates that vascular normalization and tumor perfusion
were maintained.
On the other hand, ve and VD were below pretreatment
values throughout the study; their significant reductions of
10 and 23%, respectively, were at 4 h postirradiation. At a
later point, ve and VD values slightly increased and then
remained unchanged. The remarkable decrease in ve and VD
at 4 h indicates a loss of extracellular space, suggesting that
cellular swelling may occur in tumor cells after Cilengitide
and high-dose radiation treatment. As previously reported,
cellular swelling may be a sign of tumor cell apoptosis (8,
42). Lomonaco et al. (19) found that within hours, treatment
with Cilengitide or radiation alone induced autophagy in
glioma cells; pretreatment of glioma cells with Cilengitide
prior to irradiation resulted in a larger increase in autophagy
followed by cell apoptosis and more significant increase in
cell death. It appears that Cilengitide sensitizes tumor cells
to radiation when radiation is administrated at the vascular
normalization time, thus causing tumor cell swelling, which
may either induce or signal tumor cell apoptosis. Unlike the
1 h group, the sizeable decrease in ve and VD and then the
lack of response in later time points serve as a signature of
the beneficial timing of Cilengitide and irradiation.
Apparent diffusion coefficient did not show any change in
either the 1 or 8 h group throughout the experiment period .
It demonstrated a lack of sensitivity to the acute tumor
responses hours after Cilengitide and irradiation. In a
previously published study, the sensitivity of ADC as a
biomarker was explored acutely after anti-angiogenic
treatment in a U87 orthotopic mouse glioma model. Only
very small changes in ADC were observed 2–3 days after
treatment, and ADC was found not to be a sensitive
biomarker to anti-VEGF therapy (35).
At 4 h postirradiation, Ktrans, TBF, ve and VD showed a
lack of response and maintained their values near
pretreatment levels. Consequently, we hypothesized that 4
h postirradiation was the signature time point of a beneficial
response. The difference between the 1 and 8 h groups at 4
h postirradiation is noteworthy; here, the significant changes
occur and differentiate the responses between the two
groups (Fig. 5). At 2 h postirradiation, all vascular
parameters for the 1 and 8 h groups are similar, whereas
at 4 h postirradiation, the vascular parameter values diverge.
Specifically, when the 1 and 8 h groups are compared, TBF,
Ktrans and VD values were significantly different 4 h
postirradiation (P ¼ 0.010, 0.030 and 0.032, respectively).
It appears that at 4 h postirradiation the combined
treatments has a superior therapeutic effect on the tumor
cells, and that this effect remained at later time points. Our
assumption, supported by the data, is that tumor vasculature
and cells are most vulnerable at 4–12 h postirradiation.
Therefore, in the event that other therapeutic agents are
intended to be delivered in conjunction with the combined
treatments discussed here, 4–12 h postirradiation appears to
be the optimal time for administration.
In this work, tumor oxygenation was not directly
measured, although it is known that oxygenation levels in
tumors are a critical factor in response to radiation.
However, since perfusion and distribution volume was
measured, it is probable that surrogate measures of tumor
oxygenation were available, at least for the tumor as a
whole. With that in mind, it might be hypothesized that the
preservation of flow in the 8 h group at the early time points
after irradiation indicated an overall increase in oxygenation
in the tumor, compared to the 1 h group and a subsequent
improvement in response to radiation.
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The findings from this study certainly have clinical
implications. The drug Cilengitide entered phase III clinical
trials [the CENTRIC EORTC 26071-22072 study (43)] for
the treatment of gliomas; it was administered in addition to
standard TMZ and radiotherapy. The result of this trial
showed that the use of Cilengitide does not extend the OS in
newly diagnosed GBM patients. However, it is worth noting
that in the CENTRIC study, Cilengitide was administered
without regard to optimal timing with radiotherapy. Thus,
one of the reasons that Cilengitide may have shown no
benefit in this trial may be that the critical matter of timing
and the short-term effects of Cilengitide were not
considered. Also, a lack of knowledge about the acute
physiology of tumor response in the hours after combined
treatments may have contributed to a missed opportunity to
optimally combine these two treatments.
Exposure to radiation at the vascular normalization time
window triggered by Cilengitide can lead to an amplifica-
tion in the outcome of radiation exposure. In the 8 h group,
our results support Cilengitide increasing the effectiveness
of radiation injury through a change in the tumor
environment and by increasing radiation-induced apoptosis
and vascular normalization.
Acute changes in physiology may guide the optimization
of other anti-angiogenic agents used in combination with
radiation treatment. Recently, two placebo-controlled,
randomized trials were conducted by the U.S. Radiation
Therapy Oncology Group (RTOG) 0825 trial and the
European Avastin in Glioblastoma (AVAglio) trial. These
trials addressed the clinical benefit of adding bevacizumab
to the best standard treatment for newly diagnosed GBM
(radiotherapy and temozolomide). While the two trials were
nearly identical in design, patient characteristics and the
primary end points of progression-free survival and overall
survival, the study results were contradictory. The U.S.
study reported no benefit with the combined treatments
(44), whereas the European study showed improved
progression-free survival, maintenance of baseline quality
of life and performance status, although no benefit to overall
survival was reported (45). The reason for the difference
remains unclear (46). The identification of a subset of
patients that would benefit from the addition of bevacizu-
mab was noted, and a call was made for the development of
imaging markers and biomarkers that may be predictive of a
response to bevacizumab in an individual patient (46). The
MRI findings described herein may serve as an early
predictor of tumor response based on the responsiveness of
tumor vasculature and may have value for distinguishing
those eventual responders from the nonresponders.
Furthermore, it has been recommended elsewhere (3, 47,
48) that the use of a combination of multi-pathway-targeted
agents with conventional chemo-radiotherapy may improve
the treatment outcome in GBMs. We believe that if
treatments are combined in an informed manner, based on
acute changes in tumor vascular parameters, they may offer
a superior outcome; the sequence and delivery time between
treatments may have a crucial impact on outcome and
survival. Tracking the short-term changes in tumor
physiology after a single treatment or combined treatments
may help define the sequence and timing for an optimum
FIG. 5. Comparison of percentage changes between the 1 and 8 h groups for each parameter. Panels A–D:
TBF, Ktrans, VD and ve, respectively. Notably, there is great divergence in the vascular parameter values at the 4 h
time point between the 1 and 8 h groups where the significant changes occur. TBF, Ktrans and VD values for the 1
and 8 h groups were significantly different at 4 h postirradiation (P ¼ 0.010, 0.030 and 0.032, respectively),
while ve was not significantly different (P¼ 0.071). In contrast, ADC did not show any difference or particular
pattern between 1 and 8 h groups (data not shown).
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effect. The noninvasive MRI biomarkers used in this study
can be useful tools to monitor the temporal vascular changes
in tumors.
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